R-CHOP方案与CHOP方案治疗早期初治胃弥漫大B细胞淋巴瘤效果比较  

Comparative study on effect of R-CHOP regimen and CHOP regimen for the treatment of newly diagnosed patients with early-stage primary gastric diffuse large B-cell lymphoma

作　　者：崔天祥[1] 徐燕梅[1] 金俊余[1] 孙建国[1] 

机构地区：[1]第三军医大学新桥医院全军肿瘤研究所,重庆400037

出　　处：《肿瘤研究与临床》2015年第9期605-608,共4页Cancer Research and Clinic

摘　　要：目的：比较R-CHOP方案与CHOP方案治疗早期初治胃弥漫大B细胞性淋巴（PG-DLBCL）的效果。方法回顾性分析2000年7月至2010年7月收治的65例早期初治PG-DLBCL患者的临床资料，其中R-CHOP组35例，CHOP组30例，比较两组患者的近期疗效、生存率及不良反应。结果 R-CHOP组完全缓解（CR）率为74.3%（26／35），CHOP组为50.0%（15／30）（P＜0.05），两组不良反应发生率差异无统计学意义（P＞0.05）。 Kaplan-Meier生存分析显示R-CHOP组5年生存率高于CHOP组（88.6%比75.0%），但两组差异无统计学意义（P＞0.05）；R-CHOP组无进展生存（PFS）优于CHOP组（94.4个月比74.9个月），两组差异有统计学意义（P＜0.05）。结论 R-CHOP方案治疗早期初治PG-DLBCL近期疗效较好，能够提高CR率，延长PFS，且不增加全身不良反应。Objective To compare the effect and safety of rituximab plus CHOP （R-CHOP） and CHOP regimens for the treatment of newly diagnosed patients with early-stage primary gastric diffuse large B-cell lymphoma （PG-DLBCL）. Methods A total of 65 patients with PG-DLBCL were retrospectively divided into two groups： 35 patients were treated with R-CHOP regimen, the others with CHOP regimen. NHL international efficacy assessment and WHO criteria were used to assess the therapeutic and the adverse reactions respectively. Results The complete remission （CR） rate of R-CHOP group was 74.3 % （26/35）, which was significantly higher than that of CHOP group [50.0 % （15/30）, P〈 0.05], but the adverse reactions rates of two groups had no significant difference （P〉0.05）. The Kaplan-Meier survival analysis showed that the five-year survival rates of two groups had no significant difference （88.6%vs 75.0%, P〉0.05）. The PFS of R-CHOP group was better than that of CHOP group （94.4 months vs 74.9 months, P〈 0.05）. Conclusion Compared with CHOP regimen , R-CHOP regimen increases the therapeutic efficacy in patients with PG-DLBCL, and dose not increase the adverse reactions.

关 键 词：胃肿瘤 淋巴瘤 大B细胞 弥漫型 抗肿瘤联合化疗方案 

分 类 号：R735.2[医药卫生—肿瘤]